MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance [Yahoo! Finance]
MIRA Pharmaceuticals, Inc. (MIRA)
Company Research
Source: Yahoo! Finance
MIAMI, FL / ACCESSWIRE / July 22, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. The additional data announced today continues a string of promising preclinical results announced by MIRA in recent months for Ketamir-2 as MIRA works towards its goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of this year which, if granted, would allow for human testing of Ketamir-2. Ketamir-2 is under investigation for its potential in treating neurological and neuropsychiatric disorders, including depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD). Ketamir-2: Brain Penetration and Therapeutic Potential Ketamir-2 has demonstrated in in vitro studies that it is not a substrate for interaction with P-glycoprote
Show less
Read more
Impact Snapshot
Event Time:
MIRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRA alerts
High impacting MIRA Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MIRA
News
- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
- MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024Accesswire
- MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025Accesswire
- MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA [Yahoo! Finance]Yahoo! Finance
MIRA
Sec Filings
- 9/27/24 - Form 424B5
- 9/27/24 - Form S-8
- 9/12/24 - Form 8-K
- MIRA's page on the SEC website